H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
31. Bar<strong>lo</strong>gie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E,<br />
van Rhee F, et al. Thalidomide and hematopoietic-cell transplantat<strong>io</strong>n<br />
for multiple mye<strong>lo</strong>ma. N Engl J Med. 2006;354:1021-30.<br />
32. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C,<br />
Benboubker L, et al. Maintenance therapy with thalidomide<br />
improves survival in multiple mye<strong>lo</strong>ma patients. B<strong>lo</strong>od. 2006;<br />
15:3289-94.<br />
33. Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF,<br />
Coyle L, et al. Consolidat<strong>io</strong>n therapy with <strong>lo</strong>w-dose thalidomide<br />
and predniso<strong>lo</strong>ne pro<strong>lo</strong>ngs the survival of multiple<br />
mye<strong>lo</strong>ma patients undergoing a single auto<strong>lo</strong>gous stem-cell<br />
transplantat<strong>io</strong>n procedure. J Clin Oncol. 2009;27:1788-93.<br />
34. Lokhorst HM, van der Holt B, Zweegman S, Vellenga E,<br />
Croockewit S, van Oers MH, et al. A randomized phase 3<br />
study on the effect of thalidomide combined with adriamycin,<br />
dexamethasone, and high-dose melphalan, fol<strong>lo</strong>wed by<br />
thalidomide maintenance in patients with multiple mye<strong>lo</strong>ma.<br />
B<strong>lo</strong>od. 2010;115:1113-20.<br />
35. Attal M, Cristini C, Marit G, Cail<strong>lo</strong>t D, Facon T, Hullin C, et<br />
al. Lenalidomide maintenance after transplantat<strong>io</strong>n for mye<strong>lo</strong>ma.<br />
J Clinl Oncol. 2010;28(15): 8018a.<br />
36. McCarthy PL, Owzar K, Anderson KC, Hofmeister CC,<br />
Hassoun H, Hurd DD, et al. Phase III intergroup study of<br />
lenalidomide versus placebo maintenance therapy fol<strong>lo</strong>wing single<br />
auto<strong>lo</strong>gous stem cell transplant (ASCT) for multiple mye<strong>lo</strong>ma<br />
(MM): CALGB 100104. J Clin Oncol. 2010;28(15):8017a.<br />
37. Bar<strong>lo</strong>gie B, Anaissie E, van Rhee F, Haessler J, Hollmig K,<br />
Pineda-Roman M, et al. Incorporating bortezomib into<br />
upfront treatment for multiple mye<strong>lo</strong>ma: early results of total<br />
therapy 3. Br J Haematol. 2007;138:176-85.<br />
38. van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S,<br />
Alsayed Y, et al. Total therapy 3 for multiple mye<strong>lo</strong>ma: prognostic<br />
implicat<strong>io</strong>ns of cumulative dosing and premature discontinuat<strong>io</strong>n<br />
of VTD maintenance components, bortezomib,<br />
thalidomide, and dexamethasone, relevant to all phases of<br />
therapy. B<strong>lo</strong>od. 2010;116:1220-7.<br />
39. Moreau P, Hulin C, Facon T. Frontline treatment of multiple<br />
mye<strong>lo</strong>ma in elderly patients. B<strong>lo</strong>od Rev. 2008;22:303-9.<br />
40. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM,<br />
Migl<strong>io</strong>re PJ, et al. Treatment for multiple mye<strong>lo</strong>ma. Combinat<strong>io</strong>n<br />
chemotherapy with different dose regimens. JAMA. 1969;208:<br />
1680-5.<br />
41. Mye<strong>lo</strong>ma Trialists’Collaborative Group. Combinat<strong>io</strong>n<br />
chemotherapy versus melphalan and prednisone as treatment<br />
for multiple mye<strong>lo</strong>ma: an overview of 6633 patients from 27<br />
randomized trials. J Clin Oncol. 1998;16:3832-42.<br />
42. Facon T, Mary JY, Pégourie B, Attal M, Renaud M, Sadoun A,<br />
et al. Dexamethasone-based regimens versus melphalan-prednisone<br />
for elderly multiple mye<strong>lo</strong>ma patients ineligible for<br />
high-dose therapy. B<strong>lo</strong>od. 2006;107:1292-8.<br />
43. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V,<br />
Callea V, et al. Oral melphalan and prednisone chemotherapy<br />
plus thalidomide compared with melphalan and prednisone<br />
a<strong>lo</strong>ne in elderly patients with multiple mye<strong>lo</strong>ma: randomised<br />
controlled trial. Lancet. 2006;367:825-31.<br />
44. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B,<br />
et al. Melphalan and prednisone plus thalidomide versus melphalan<br />
and prednisone a<strong>lo</strong>ne or reduced-intensity auto<strong>lo</strong>gous<br />
stem cell transplantat<strong>io</strong>n in elderly patients with multiple mye<strong>lo</strong>ma<br />
(IFM99-06): a randomised trial. Lancet. 2007;370:1209-18.<br />
45. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen<br />
C, et al. Efficacy of melphalan and prednisone plus thalido-<br />
London, United Kingdom, June 9-12, 2011<br />
mide in patients older than 75 years with newly diagnosed<br />
multiple mye<strong>lo</strong>ma: IFM 01/01 trial. J Clin Oncol. 2009;27:<br />
3664-70.<br />
46. Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L,<br />
Björkstrand B, et al. Melphalan and prednisone plus thalidomide<br />
or placebo in elderly patients with multiple mye<strong>lo</strong>ma.<br />
B<strong>lo</strong>od. 2010;116:1405-12.<br />
47. Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R,<br />
Wittebol S, Sinnige H, et al. Phase III study of the value of<br />
thalidomide added to Melphalan plus prednisone in elderly<br />
patients with newly diagnosed multiple mye<strong>lo</strong>ma: the<br />
HOVON 49 study. J Clin Oncol. 2010;28:3160-6.<br />
48. Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H,<br />
Aydogdu I, Konuk N, et al. Addit<strong>io</strong>n of thalidomide to oral<br />
Melphalan/prednisone in patients with multiple mye<strong>lo</strong>ma not<br />
eligible for transplantat<strong>io</strong>n: results of a randomized trial from<br />
the Turkish Mye<strong>lo</strong>ma Study Group. Eur J Haematol. 2011;<br />
86:16-22.<br />
49. Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC,<br />
Pa<strong>lo</strong>mera L, Fuertes M, et al. Bortezomib plus melphalan and<br />
prednisone in elderly untreated patients with multiple mye<strong>lo</strong>ma:<br />
results of a multicenter phase 1 / 2 study. B<strong>lo</strong>od 2006;<br />
108:2165-72.<br />
50. San Miguel JF, Schlag R, Khuageva NK, Dimopou<strong>lo</strong>s MA,<br />
Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and<br />
prednisone for initial treatment of multiple mye<strong>lo</strong>ma. N Engl J<br />
Med. 2008;359:906-17.<br />
51. Mateos MV, Or<strong>io</strong>l A, Martínez-López J, Gutiérrez N, Teruel<br />
AI, de Paz R, et al. Bortezomib, melphalan, and prednisone<br />
versus bortezomib, thalidomide, and prednisone as induct<strong>io</strong>n<br />
therapy fol<strong>lo</strong>wed by maintenance treatment with bortezomib<br />
and thalidomide versus bortezomib and prednisone in elderly<br />
patients with untreated multiple mye<strong>lo</strong>ma: a randomised trial.<br />
Lancet Oncol. 2010;11:934-41.<br />
52. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R,<br />
et al. Bortezomib-melphalan-prednisone-thalidomide fol<strong>lo</strong>wed<br />
by maintenance with bortezomib-thalidomide compared<br />
with bortezomib-melphalan-prednisone for initial treatment<br />
of multiple mye<strong>lo</strong>ma: a randomized controlled trial. J<br />
Clin Oncol. 2010;28:5101-9.<br />
53. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F,<br />
Giuliani N, et al. Melphalan, prednisone, and lenalidomide<br />
treatment for newly diagnosed mye<strong>lo</strong>ma: a report from the<br />
GIMEMA--Italian Multiple Mye<strong>lo</strong>ma Network. J Clin Oncol.<br />
2007;25:4459-65.<br />
54. Anton<strong>io</strong> Palumbo, Michel Delforge, John Catalano, Roman<br />
Hajek, Martin Kropff, Maria Teresa Petrucci, et al. A phase 3<br />
evaluating the efficacy and safety of lenalidomide combined<br />
with melphalan and prednisone in patients > 65 years with<br />
newly diagnosed multiple mye<strong>lo</strong>ma: continuous use of<br />
lenalidomide vs fixed-durat<strong>io</strong>n regimens. B<strong>lo</strong>od (ASH Annual<br />
Meeting Abstracts) Nov 2010;116:622a.<br />
55. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer<br />
SM, Kabat B, et al. Combinat<strong>io</strong>n therapy with lenalidomide<br />
plus dexamethasone for newly diagnosed mye<strong>lo</strong>ma. B<strong>lo</strong>od.<br />
2005;106:4050-3.<br />
56. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH,<br />
Williams ME, et al. Lenalidomide plus high-dose dexamethasone<br />
versus lenalidomide plus <strong>lo</strong>w-dose dexamethasone as<br />
initial therapy for newly diagnosed multiple mye<strong>lo</strong>ma: an<br />
open-label randomised controlled trial. Lancet Oncol. 2010;<br />
11:29-37.<br />
Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1) | 293 |